Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
In one aspect, the invention relates to bicyclic MGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
1. A compound that exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound, comprising:
wherein n is 2, 3 or 4;
wherein R 1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R 2a and R 2b together comprise ═O or ═S or each R 2a and R 2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R 5 is an organic radical comprising 4 to 14 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
wherein Y 1 is selected from N and C—R 4 ;
wherein Y 2 is selected from N and C—H;
wherein each R 3a and R 3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R 4 is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms.
2. A compound that exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound, selected from:
3. A compound that exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound, selected from:
4. A compound that exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound, selected from:
5. A compound that exhibits potentiation of mGluR5 response to glutamate as an increase in response to non-maximal concentrations of glutamate in human embryonic kidney cells transfected with rat mGluR5 in the presence of the compound, compared to the response to glutamate in the absence of the compound, selected from:
6. The compound of claim 1 , wherein R 1 is an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, and —(CH 2 ) m -aryl or —(CH 2 ) m -heterocycle, wherein m is 1, 2, 3 or 4.
7. The compound of claim 1 , wherein R 2a and R 2b , when present, together comprise ═O or ═S or each R 2a and R 2b is independently an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C3-C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
8. The compound of claim 1 , wherein each R 3a and R 3b is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or independently an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C3-C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
9. The compound of claim 1 , wherein R 4 , when present, is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms independently selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
10. The compound of claim 1 , wherein R 5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl.
11. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 2 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 3 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 4 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 5 and a pharmaceutically acceptable carrier.
16. A method for the treatment of schizophrenia in a mammal comprising the step of administering to the mammal at least one compound having a structure:
wherein n is 2, 3 or 4;
wherein R 1 is hydrogen or an organic radical comprising 1 to 12 carbon atoms;
wherein R 2a and R 2b together comprise ═O or ═S or each R 2a and R 2b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms;
wherein R 5 is an organic radical comprising 4 to 14 carbon atoms,
wherein Y 1 is selected from N and C—R 4 ;
wherein Y 2 is selected from N and C—H;
wherein each R 3a and R 3b is independently hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or an organic radical comprising 1 to 6 carbon atoms; and
wherein R 4 is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms,
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to treat the schizophrenia in the mammal.
17. The method of claim 16 , wherein the mammal is a human.
18. The method of claim 16 , wherein the mammal has been diagnosed with a need for treatment of the schizophrenia prior to the administering step.
19. A method for the treatment of schizophrenia in a mammal comprising the step of administering to the mammal at least one compound having a structure selected from:
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to treat the schizophrenia in the mammal.
20. A method for the treatment of schizophrenia in a mammal comprising the step of administering to the mammal at least one compound having a structure selected from:
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to treat the schizophrenia in the mammal.
21. A method for the treatment of schizophrenia in a mammal comprising the step of administering to the mammal at least one compound having a structure selected from:
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to treat the schizophrenia in the mammal.
22. A method for the treatment of schizophrenia in a mammal comprising the step of administering to the mammal at least one compound having a structure selected from:
or a pharmaceutically acceptable salt or N-oxide thereof,
in a dosage and amount effective to treat the schizophrenia in the mammal.
23. The method of claim 19 , wherein the mammal is a human.
24. The method of claim 19 , wherein the mammal has been diagnosed with a need for treatment of the schizophrenia prior to the administering step.
25. The method of claim 20 , wherein the mammal is a human.
26. The method of claim 20 , wherein the mammal has been diagnosed with a need for treatment of the schizophrenia prior to the administering step.
27. The method of claim 21 , wherein the mammal is a human.
28. The method of claim 21 , wherein the mammal has been diagnosed with a need for treatment of the schizophrenia prior to the administering step.
29. The method of claim 22 , wherein the mammal is a human.
30. The method of claim 22 , wherein the mammal has been diagnosed with a need for treatment of the schizophrenia prior to the administering step.
31. The method of claim 16 , wherein R 1 is an organic radical comprising 1 to 12 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, and —(CH 2 ) m -aryl or —(CH 2 ) m -heterocycle, wherein m is 1, 2, 3 or 4.
32. The method of claim 16 , wherein R 2a and R 2b , when present, together comprise ═O or ═S or each R 2a and R 2b is independently an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C3-C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
33. The method of claim 16 , wherein each R 3a and R 3b is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, amino, or independently an organic radical comprising 1 to 6 carbon atoms selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C6 cycloalkyl or C3-C6 cycloalkenyl or C3-C6 cycloalkynyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl or C6 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
34. The method of claim 16 , wherein R 4 , when present, is hydrogen, halogen, hydroxyl, cyano, nitro, thiol, or an organic radical comprising 1 to 12 carbon atoms independently selected from optionally substituted C1-C6 alkyl or C2-C6 alkenyl or C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl or C2-C6 heteroalkenyl or C2-C6 heteroalkynyl, optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl or C6-C8 cycloalkynyl, optionally substituted C3-C8 heterocycloalkyl or C3-C8 heterocycloalkenyl or C6-C8 heterocycloalkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkoxyl, optionally substituted thioalkyl, optionally substituted alkylsulfinyl, optionally substituted alkylsulfonyl, and optionally substituted amino, thioamido, amidosulfonyl, alkoxycarbonyl, carboxamide, amino-carbonyl, and alkylamine-carbonyl.
35. The method of claim 16 , wherein R 5 is an organic radical comprising 4 to 14 carbon atoms selected from optionally substituted C3-C8 cycloalkyl or C3-C8 cycloalkenyl, optionally substituted C3-C6 heterocycloalkyl or C3-C6 heterocycloalkenyl, optionally substituted aryl, and optionally substituted heteroaryl.